AllerGen researcher Dr. Kelly McNagny named Co-Scientific Director of CDRD

Dr. Kelly McNagny has been named a Co-Scientific Director of the Centre for Drug Research and Development (CDRD)—a national not-for-profit that speeds the development and commercialization of new drugs and health technologies emerging from Canada’s universities and research hospitals.

Dr. McNagny is a stem cell biologist and a professor in the Department of Medical Genetics at The University of British Columbia (UBC). His AllerGen research focuses on a protein called CD34 as a therapeutic target for allergic inflammation and asthma, as well as the analysis of the cellular composition of blood to predict susceptibility to allergic disease.

In his new role at CDRD, Dr. McNagny will work alongside Dr. Michael Rudnicki (Professor, Department of Medicine, University of Ottawa) and provide leadership and direction in the translation of research discoveries into new therapies for Canadians.